
There Is Value To Being At The Center Of The JPM Universe
Rob Wright provides a bit of his perspective on the 37th Annual J.P. Morgan Healthcare Conference.
Continue Reading..

From Radboud UMC To Pivot Park — Day 2 Of The Netherlands' Biopharma Press Tour
Rob Wright shares experiences from day two of recent press tour of the Netherlands’ biopharmaceutical industry.
Continue Reading..

CNS Summit 2018 Does Not Meet Expectations — It Exceeded Them
Rob Wright shares what makes the CNS Summit the best conference he has ever attended.
Continue Reading..

The Netherlands — More Than Just The New Home Of The EMA
What sets the Netherlands biopharma sector apart from the rest of the world? That’s what Chief Editor Rob Wright hoped to find out as he began his press tour of the country’s biopharma industry.
Continue Reading..

Can China Be Trusted?
Rob Wright discusses China’s history of intellectual property (IP) theft, and wonders if the government-sponsored 10-year initiative, Made in China 2025 (MIC 2025), could exacerbate the problem.
Continue Reading..

The Future Of Biopharma — Netherlands Style
Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.
Continue Reading..

What Mylan Could Learn About Accountability
Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.
Continue Reading..

Are Genetically Modified Organisms (GMO) A Blessing Or A Curse?
A question about GMOs submitted to our editorial board leads us to look more closely into this issue and how it affects the pharma industry.
Continue Reading..

Why A Biopharma Executive Founded A Game-Changing Conference
Amir Kalali, M.D., former global head of Quintiles (now IQVIA) neuroscience center of excellence, provides insight on why he decided to found an educational conference, The CNS Summit, while still working as a biopharmaceutical industry executive.
Continue Reading..

Is It Possible For A Biopharmaceutical Executive To Transcend Their Industry?
What current biopharma leaders have the potential to “transcend” beyond this industry? Chief Editor Rob Wright gives his top three choices.
Continue Reading..
This website uses cookies to ensure you get the best experience on our website. Learn more